A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-09-18
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 45); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 146); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-13 (study day 200); relationship: not assessed
Grade 1 Fatigue — outcome: UNKNOWN; onset 2024-03-18 (study day 540); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-30 (study day 552); relationship: not assessed
Data queries
No data queries.